NCT05661552CompletedPhase 4
Effect of Early Initiation of Evolocumab on Lipid Profiles Changes in Patients With ACS Undergoing PCI
Effect of Early Initiation of Evolocumab and Combination Lipid-lowering Agent on Lipid Profiles Changes in Patients With Acute Coronary Syndrome Undergoing percuTAneous coronaRy Intervention: a Prospective, Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 13 Mar 2025
Brief summary (registry, in English)
Investigators aimed to evaluate efficacy and safety of early Initiation of evolocumab and combination lipid-lowering agent (statin + Ezetimibe) on lipid profiles changes in patients with ACS undergoing PCI
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 108 (actual)
- First submitted
- 5 Dec 2022
- Start date
- 1 Dec 2022
- Primary completion date
- 5 Feb 2025
- Lead sponsor
- Yonsei University
- Diseases
- Coronary artery disease
- NCT number
- NCT05661552
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 108
- From 1 Dec 2022 to the primary completion date, 5 Feb 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who have previously taken statins,
Other illness
- If you have an allergic or hypersensitivity reaction to Evorucumab, statin, or Ezetimib,
Lab values
- Patients with active liver disease or patients with three times or more increase in AST or ALT
Age
- Pregnant women, lactating women, or women of childbearing age who plan to become pregnant during this study
Other
- The remaining life expectancy is expected to be less than a year.
- Subjects who visited the hospital due to psychogenic shock and are expected to be less likely to survive by medical judgment
- Subjects participating in a randomized clinical trial of medical devices/pharmaceuticals
Who the study is looking for
- Over 19 years old
- Patients who agreed to the research protocol and clinical follow-up survey plan, decided to participate in this study voluntarily, and gave written consent to the informed consent form.
- Patients who underwent percutaneous coronary stenting for acute coronary syndrome
Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Yongcheol Kim Coordinator of this site? Confirm its status | Yongin | South Korea | Unknown status |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.